Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

135.53USD
15 Dec 2017
Change (% chg)

$0.03 (+0.02%)
Prev Close
$135.50
Open
$135.35
Day's High
$136.62
Day's Low
$134.62
Volume
312,586
Avg. Vol
155,951
52-wk High
$163.69
52-wk Low
$102.65

Chart for

About

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $8,797.71
Shares Outstanding(Mil.): 60.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

Pennsylvania man admits to trading on tips about drug company

A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired.

15 Dec 2017

Pennsylvania man admits to trading on tips about drug company

Dec 15 A Pennsylvania man pleaded guilty on Friday to charges that he traded on confidential, inside information that a former Celator Pharmaceuticals Inc employee supplied him, including that the company now owned by Jazz Pharmaceuticals Plc was planning to be acquired.

15 Dec 2017

BRIEF-Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer

* JAZZ PHARMACEUTICALS ANNOUNCES APPOINTMENT OF DANIEL SWISHER AS PRESIDENT AND CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

04 Dec 2017

BRIEF-Jazz Pharmaceuticals posts Q3 EPS of $1.03

* Jazz pharmaceuticals announces third quarter 2017 financial results

07 Nov 2017

BRIEF-Jazz Pharma submits Vyxeo Marketing Authorization Application to European Medicines Agency

* Jazz Pharmaceuticals submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for treatment of certain types of high-risk acute myeloid leukemia Source text for Eikon: Further company coverage:

03 Nov 2017

BRIEF-Jazz Pharma announces $500 mln offering of 1.50 pct exchangeable senior notes due 2024

* Jazz Pharmaceuticals Plc - ‍offering of $500 million aggregate principal amount of 1.50% exchangeable senior notes due 2024​

18 Aug 2017

BRIEF-Jazz Pharmac announces offering of $500 mln of exchangeable senior notes

* Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024

17 Aug 2017

BRIEF-Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56

* Jazz Pharmaceuticals announces second quarter 2017 financial results

08 Aug 2017

BRIEF-Jazz Pharmaceuticals announces FDA approval of Vyxeos

* Jazz Pharmaceuticals announces FDA approval of Vyxeos™ (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

03 Aug 2017

BRIEF-Jazz Pharmaceuticals and XL-protein GmbH enter into license agreement

* Jazz Pharmaceuticals and XL-protein GmbH enter into a license agreement on PASylation technology to develop long-acting asparaginase product candidates

26 Jul 2017

Earnings vs. Estimates